ReviewAnnual review of genetics2020
Genetic Diversity in
Review in Annual review of genetics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 45 citations in OpenAlex.
- Comparative evaluation of three commercial real-time PCR kits for direct detection ofMicrobiology spectrum · 2026Article
- Strain diversity drives heterogeneous responses to tuberculosis combination therapy.Antimicrobial agents and chemotherapy · 2026Article
- Molecular Epidemiology ofMicroorganisms · 2025Review
- Strain diversity drives heterogeneous responses to tuberculosis combination therapy.bioRxiv : the preprint server for biology · 2025Article
- Diagnostic Accuracy of AdvanSureDiagnostics (Basel, Switzerland) · 2025Article
- Mycobacterial Phenolic Glycolipid Triggers ATP-Mediated Neuronal P2X3 Signaling and Cough.bioRxiv : the preprint server for biology · 2025Article
- Interred mechanisms of resistance and host immune evasion revealed through network-connectivity analysis ofmSystems · 2025Article
- Genetically Diverse Mycobacterium tuberculosis Isolates Manipulate Inflammasome and Interleukin 1β Secretion Independently of Macrophage Metabolic Rewiring.The Journal of infectious diseases · 2025Article
- Experimental dissection of tuberculosis protective immunity: a human perspective.Frontiers in cellular and infection microbiology · 2025Review
- Molecular characteristics of drug-susceptible Mycobacterium tuberculosis clinical isolates based on treatment duration.Osong public health and research perspectives · 2024Article
- PersistentiScience · 2024Article
- Review
- First Indonesian report of WGS-based MTBC L3 discovery.BMC research notes · 2024Article
- Seroepidemiological study on coinfection of toxoplasmosis and active tuberculosis in Northern Iran: a case control study.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Multidrug-resistant tuberculosis.Nature reviews. Disease primers · 2024Review
- Rapid and accurate identification and differentiation ofFrontiers in public health · 2024Article
- Epidemiological features of tuberculosis in the Middle East and North Africa from 1990 to 2019: results from the global burden of disease Study 2019.African health sciences · 2023Article
- A CRISPR-guided mutagenic DNA polymerase strategy for the detection of antibiotic-resistant mutations inMolecular therapy. Nucleic acids · 2022Article
- Understanding drivers of phylogenetic clustering and terminal branch lengths distribution in epidemics ofeLife · 2022Article
- Characterization of a class II ketol-acid reductoisomerase fromRSC advances · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Tuberculosis claims more human lives than any other bacterial infectious disease and represents a clear and present danger to global health as new tools for vaccination, treatment, and interruption of transmission have been slow to emerge. Additionally, tuberculosis presents with notable clinical heterogeneity, which complicates diagnosis, treatment, and the establishment of nonrelapsing cure. How this heterogeneity is driven by the diversity ofclinical isolates of the causative agent,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.